, Tracking Stock Market Picks
Enter Symbol:
Shire Plc (SHPG) [hlAlert]

up 235.91 %

Shire Plc (SHPGY) rated Outperform with price target $47 by Robert W. Baird

Posted on: Friday,  Mar 6, 2009  8:25 AM ET by Robert W. Baird

Robert W. Baird rated Outperform Shire Plc (NASDAQ: SHPG) on 03/06/2009. Previously Robert W. Baird rated Outperform Shire Plc (NASDAQ: SHPG) on
01/09/2008., when the stock price was $69.35. Since then, Shire Plc has gained 235.92% as of 01/12/2016's recent price of $232.96.
If you would have followed the previous Robert W. Baird's recommendation on SHPG, you would have gained 235.91% of your investment in 2925 days.

Shire plc, formerly Shire Ltd. is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), and gastrointestinal (GI) diseases, as well as opportunities in other therapeutic areas. Substantially all of the Company?s revenues and net assets are attributable to the research and development (R&D), manufacture, sale and distribution of pharmaceutical products within two operating segments: Specialty Pharmaceuticals and HGT. The Company?s key marketed products as of December 31, 2008, include VYVANSE; DAYTRANA; ADDERALL XR; PENTASA; LIALDA/ MEZAVANT; FOSRENOL; CALCICHEW; CARBATROL; REMINYL/REMINYL XL; XAGRID; REPLAGAL; ELAPRASE, and FIRAZYR.

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/6/2009 8:25 AM Buy
33.85 47.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/9/2008 8:25 AM Buy
69.35 84.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy